{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:41Z","timestamp":1790985641062,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The best method to deliver intraperitoneal chemotherapy (IPC) for peritoneal carcinomatosis from ovarian cancer is not well defined. The aim of this study was to assess the ability of hyperthermia and adrenaline to enhance the intratumoral accumulation of cisplatin in a rat model of peritoneal carcinomatosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Four groups of 5 BDIX rats with ovarian peritoneal carcinomatosis underwent IPC with 30 mg\/l of cisplatin according to the following conditions: normothermia at 37\u00b0 for 1 or 2 hours, hyperthermia at 42\u00b0C for 1 hour or normothermia at 37\u00b0C for 2 hours with 2 mg\/l adrenaline. Tissue platinum content was measured by atomic absorption spectroscopy. The effect of hyperthermia, adrenaline and the duration of exposure to the drug was measured <jats:italic>in vivo<\/jats:italic> (tissue concentration of platinum in tumor, abdominal and extra abdominal tissues) and <jats:italic>in vitro<\/jats:italic> (cytotoxicity on human ovarian cancer cells).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>\n              <jats:italic>In vitro<\/jats:italic>, hyperthermia and longer exposure enhanced the accumulation and the cytotoxic effect of cisplatin on cancer cells. <jats:italic>In vivo<\/jats:italic>, only the 2 hours treatment with adrenaline resulted in increased platinum concentrations. The rats treated with adrenaline showed significantly lower concentrations of cisplatin in extra peritoneal tissues than those treated with hyperthermia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Adrenaline is more effective than hyperthermia in order to enhance the intratumoral concentration of cisplatin in rats with peritoneal carcinomatosis from ovarian origin. It may also decrease the systemic absorption of the drug.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1756-9966-30-4","type":"journal-article","created":{"date-parts":[[2011,1,7]],"date-time":"2011-01-07T19:16:28Z","timestamp":1294427788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Comparison of hyperthermia and adrenaline to enhance the intratumoral accumulation of cisplatin in a murin model of peritoneal carcinomatosis"],"prefix":"10.1186","volume":"30","author":[{"given":"Olivier","family":"Facy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Radais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Ladoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Delroeux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Tixier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Ghiringhelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Rat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Chauffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Ortega-Deballon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,1,7]]},"reference":[{"key":"424_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.critrevonc.2005.03.003","volume":"55","author":"A Gadducci","year":"2005","unstructured":"Gadducci A, Cosio S, Conte PF, Genazzani AR: Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit Rev Oncol Hematol. 2005, 55: 153-66. 10.1016\/j.critrevonc.2005.03.003.","journal-title":"Crit Rev Oncol Hematol"},{"key":"424_CR2","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1046\/j.1365-2168.2002.02274.x","volume":"89","author":"DG Jayne","year":"2002","unstructured":"Jayne DG, Fook S, Loi C, Seow-Choen F: Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002, 89: 1545-50. 10.1046\/j.1365-2168.2002.02274.x.","journal-title":"Br J Surg"},{"key":"424_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1525-1438.2007.00809.x","volume":"17","author":"K Fujiwara","year":"2007","unstructured":"Fujiwara K, Armstrong D, Morgan M, Markman M: Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2007, 17: 1-20. 10.1111\/j.1525-1438.2007.00809.x.","journal-title":"Int J Gynecol Cancer"},{"key":"424_CR4","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2009","unstructured":"Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H: 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2009, 15: 2426-32. 10.1245\/s10434-008-9966-2.","journal-title":"Ann Surg Oncol"},{"key":"424_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006, 354: 34-43. 10.1056\/NEJMoa052985.","journal-title":"N Engl J Med"},{"key":"424_CR6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.ygyno.2007.02.015","volume":"105","author":"M Fung-Kee-Fung","year":"2007","unstructured":"Fung-Kee-Fung M, Provencher D, Rosen B, Hoskins P, Rambout L, Oliver T, et al: Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care. Gynecol Oncol. 2007, 105: 747-56. 10.1016\/j.ygyno.2007.02.015.","journal-title":"Gynecol Oncol"},{"key":"424_CR7","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/jnci\/djj173","volume":"98","author":"C Bankhead","year":"2006","unstructured":"Bankhead C: Intraperitoneal therapy for advanced ovarian cancer: will it become standard care?. J Natl Cancer Inst. 2006, 98: 510-2. 10.1093\/jnci\/djj173.","journal-title":"J Natl Cancer Inst"},{"key":"424_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1479-5876-4-17","volume":"4","author":"TD Yan","year":"2006","unstructured":"Yan TD, Stuart OA, Yoo D, Sugarbaker PH: Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy. J Transl Med. 2006, 4: 17-10.1186\/1479-5876-4-17.","journal-title":"J Transl Med"},{"key":"424_CR9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","volume":"27","author":"D Elias","year":"2009","unstructured":"Elias D, Lefevre JH, Chevalier J, et al: Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009, 27: 681-5. 10.1200\/JCO.2008.19.7160.","journal-title":"J Clin Oncol"},{"key":"424_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/PPO.0b013e3181a58e74","volume":"15","author":"J Esquivel","year":"2009","unstructured":"Esquivel J: Technology of hyperthermic intraperitoneal chemotherapy in the United States, Europe, China, Japan, and Korea. Cancer J. 2009, 15: 249-54. 10.1097\/PPO.0b013e3181a58e74.","journal-title":"Cancer J"},{"key":"424_CR11","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1245\/s10434-010-0937-z","volume":"17","author":"P Ortega-Deballon","year":"2010","unstructured":"Ortega-Deballon P, Facy O, Jambet S, Magnin G, Cotte E, Beltramo JL, et al: Which method to deliver heated intraperitoneal chemotherapy with oxaliplatin? An experimental comparison of open and closed techniques. Ann Surg Oncol. 2010, 17: 1957-63. 10.1245\/s10434-010-0937-z.","journal-title":"Ann Surg Oncol"},{"key":"424_CR12","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s00268-007-9146-8","volume":"31","author":"E Cotte","year":"2007","unstructured":"Cotte E, Glehen O, Mohamed F, Lamy F, Falandry C, Golfier F, et al: Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg. 2007, 31: 1813-20. 10.1007\/s00268-007-9146-8.","journal-title":"World J Surg"},{"key":"424_CR13","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ygyno.2006.10.051","volume":"105","author":"CW Helm","year":"2007","unstructured":"Helm CW, Randall-Whitis L, Martin RS, Metzinger DS, Gordinier ME, Parker LP, et al: Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol. 2007, 105: 90-6. 10.1016\/j.ygyno.2006.10.051.","journal-title":"Gynecol Oncol"},{"key":"424_CR14","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/cncr.21708","volume":"106","author":"S Kusamura","year":"2006","unstructured":"Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, et al: Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer. 2006, 106: 1144-53. 10.1002\/cncr.21708.","journal-title":"Cancer"},{"key":"424_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1477-7819-2-21","volume":"2","author":"P Piso","year":"2004","unstructured":"Piso P, Dahlke MH, Loss M, Schlitt HJ: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol. 2004, 2: 21-10.1186\/1477-7819-2-21.","journal-title":"World J Surg Oncol"},{"key":"424_CR16","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ejso.2006.03.011","volume":"32","author":"F Raspagliesi","year":"2006","unstructured":"Raspagliesi F, Kusamura S, Campos Torres JC, de Souza GA, Ditto A, Zanaboni F, et al: Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced\/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. Eur J Surg Oncol. 2006, 32: 671-5. 10.1016\/j.ejso.2006.03.011.","journal-title":"Eur J Surg Oncol"},{"key":"424_CR17","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/S1055-3207(03)00036-X","volume":"12","author":"B Chauffert","year":"2003","unstructured":"Chauffert B, Favoulet P, Polycarpe E, Duvillard C, Beltramo JL, Bichat F, et al: Rationale supporting the use of vasoconstrictors for intraperitoneal chemotherapy with platinum derivatives. Surg Oncol Clin N Am. 2003, 12: 835-48. 10.1016\/S1055-3207(03)00036-X.","journal-title":"Surg Oncol Clin N Am"},{"key":"424_CR18","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/(SICI)1097-0215(19990531)81:5<779::AID-IJC19>3.0.CO;2-I","volume":"81","author":"C Duvillard","year":"1999","unstructured":"Duvillard C, Benoit L, Moretto P, Beltramo JL, Brunet-Lecomte P, Correia M, et al: Adrenaline enhances penetration and anti-cancer activity of local cisplatin on rat sub-cutaneous and peritoneal tumors. Int J Cancer. 1999, 81: 779-84. 10.1002\/(SICI)1097-0215(19990531)81:5<779::AID-IJC19>3.0.CO;2-I.","journal-title":"Int J Cancer"},{"key":"424_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/ejso.2000.1028","volume":"27","author":"P Favoulet","year":"2001","unstructured":"Favoulet P, Magnin G, Guilland JC, Beltramo JL, Osmak L, Benoit L, et al: Pre-clinical study of the adrenaline-cisplatin association for the treatment of intraperitoneal carcinomatosis. Eur J Surg Oncol. 2001, 27: 59-64. 10.1053\/ejso.2000.1028.","journal-title":"Eur J Surg Oncol"},{"key":"424_CR20","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1097\/01.cad.0000236309.66080.3b","volume":"17","author":"C Molucon-Chabrot","year":"2006","unstructured":"Molucon-Chabrot C, Isambert N, Benoit L, Zanetta S, Fraisse J, Guilland JC, et al: Feasibility of using intraperitoneal adrenaline and cisplatin in patients with advanced peritoneal carcinomatosis. Anticancer Drugs. 2006, 17: 1211-7. 10.1097\/01.cad.0000236309.66080.3b.","journal-title":"Anticancer Drugs"},{"key":"424_CR21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/CAD.0b013e328334d953","volume":"21","author":"E Guardiola","year":"2010","unstructured":"Guardiola E, Chauffert B, Delroeux D, et al: Intraoperative intraperitoneal (IP) chemotherapy with cisplatin and epinephrine after cytoreductive surgery in patients with recurrent ovarian cancer: a phase I study. Anticancer Drugs. 2010, 21: 320-5. 10.1097\/CAD.0b013e328334d953.","journal-title":"Anticancer Drugs"},{"key":"424_CR22","first-page":"215","volume":"16","author":"B Chauffert","year":"1992","unstructured":"Chauffert B, Dimanche-Boitrel MT, Genne P, Petit JM, Onier N, Jeannin JF: Experimental chemotherapy of peritoneal carcinomatosis of colonic origin in rats. Gastroenterol Clin Biol. 1992, 16: 215-9.","journal-title":"Gastroenterol Clin Biol"},{"key":"424_CR23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ijc.2910320517","volume":"32","author":"F Martin","year":"1983","unstructured":"Martin F, Caignard A, Jeannin JF, et al: Selection by trypsin of two sublines of rat colon cancer cells forming progressive or regressive tumors. Int J Cancer. 1983, 32: 623-7. 10.1002\/ijc.2910320517.","journal-title":"Int J Cancer"},{"key":"424_CR24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00280-007-0484-x","volume":"61","author":"B Royer","year":"2008","unstructured":"Royer B, Delroeux D, Guardiola E, Combe M, Hoizey G, Montange D, et al: Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer. Cancer Chemother Pharmacol. 2008, 61: 415-21. 10.1007\/s00280-007-0484-x.","journal-title":"Cancer Chemother Pharmacol"},{"key":"424_CR25","first-page":"1165","volume":"40","author":"B Barlogie","year":"1980","unstructured":"Barlogie B, Corry PM, Drewinko B: In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum (II) and mitomycin C. Cancer Res. 1980, 40: 1165-8.","journal-title":"Cancer Res"},{"key":"424_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3109\/02656739009140803","volume":"6","author":"H Eichholtz-Wirth","year":"1990","unstructured":"Eichholtz-Wirth H, Hietel B: Heat sensitization to cisplatin in two cell lines with different drug sensitivities. Int J Hyperthermia. 1990, 6: 47-55. 10.3109\/02656739009140803.","journal-title":"Int J Hyperthermia"},{"key":"424_CR27","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/0277-5379(91)90389-U","volume":"27","author":"G Los","year":"1991","unstructured":"Los G, Sminia P, Wondergem J, Mutsaers PH, Havemen J, ten Bokkel HD, et al: Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer. 1991, 27: 472-7. 10.1016\/0277-5379(91)90389-U.","journal-title":"Eur J Cancer"},{"key":"424_CR28","first-page":"1136","volume":"40","author":"RE Meyn","year":"1980","unstructured":"Meyn RE, Corry PM, Fletcher SE, Demetriades M: Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum (II). Cancer Res. 1980, 40: 1136-9.","journal-title":"Cancer Res"},{"issue":"Suppl 5","key":"424_CR29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/1120009X.2004.11782377","volume":"16","author":"M Conti","year":"2004","unstructured":"Conti M, De GU, Tazzari V, Bezzi F, Baccini C: Clinical pharmacology of intraperitoneal cisplatin-based chemotherapy. J Chemother. 2004, 16 (Suppl 5): 23-5.","journal-title":"J Chemother"},{"key":"424_CR30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/bjc.1994.45","volume":"69","author":"G Los","year":"1994","unstructured":"Los G, van Vugt MJ, Pinedo HM: Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer. 1994, 69: 235-41.","journal-title":"Br J Cancer"},{"key":"424_CR31","first-page":"1643","volume":"23","author":"S Zeamari","year":"2003","unstructured":"Zeamari S, Floot B, van d, Stewart FA: Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC). Anticancer Res. 2003, 23: 1643-8.","journal-title":"Anticancer Res"},{"key":"424_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1593\/neo.03205","volume":"6","author":"AW El-Kareh","year":"2004","unstructured":"El-Kareh AW, Secomb TW: A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. Neoplasia. 2004, 6: 117-27. 10.1593\/neo.03205.","journal-title":"Neoplasia"},{"key":"424_CR33","first-page":"4965","volume":"52","author":"PL Ausmus","year":"1992","unstructured":"Ausmus PL, Wilke AV, Frazier DL: Effects of hyperthermia on blood flow and cis-diamminedichloroplatinum (II) pharmacokinetics in murine mammary adenocarcinomas. Cancer Res. 1992, 52: 4965-8.","journal-title":"Cancer Res"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-9966-30-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T12:41:01Z","timestamp":1630500061000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/1756-9966-30-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,7]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["424"],"URL":"https:\/\/doi.org\/10.1186\/1756-9966-30-4","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,7]]},"assertion":[{"value":"2 December 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"4"}}